Trial Watch

@inproceedings{Vacchelli2013TrialW,
  title={Trial Watch},
  author={Erika Vacchelli and Alexander Eggermont and Wolf H Fridman and J{\'e}r{\^o}me Galon and Eric Tartour and Laurence Zitvogel and Guido Kroemer and Lorenzo Galluzzi},
  booktitle={Oncoimmunology},
  year={2013}
}
Adoptive cell transfer (ACT) represents a prominent form of immunotherapy against malignant diseases. ACT is conceptually distinct from dendritic cell-based approaches (which de facto constitute cellular vaccines) and allogeneic transplantation (which can be employed for the therapy of hematopoietic tumors) as it involves the isolation of autologous lymphocytes exhibiting antitumor activity, their expansion/activation ex vivo and their reintroduction into the patient. Re-infusion is most often… CONTINUE READING

References

Publications referenced by this paper.
SHOWING 1-10 OF 150 REFERENCES

Raising the bar: the curative potential of human cancer immunotherapy.

  • Science translational medicine
  • 2012
VIEW 12 EXCERPTS
HIGHLY INFLUENTIAL

Cancer immunotherapy comes of age.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2011
VIEW 9 EXCERPTS
HIGHLY INFLUENTIAL

Cell transfer immunotherapy for metastatic solid cancer—what clinicians need to know

  • Nature Reviews Clinical Oncology
  • 2011
VIEW 10 EXCERPTS
HIGHLY INFLUENTIAL

BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2013

Similar Papers

Loading similar papers…